Mixed-Grade Urothelial Carcinoma: Insights Into Clinical Behavior and Prognostic Implications Compared to Pure Low-Grade and High-Grade Urothelial Carcinomas.

Fateme Khalatbari, Miremad Moafi-Madani, Ali Amin
{"title":"Mixed-Grade Urothelial Carcinoma: Insights Into Clinical Behavior and Prognostic Implications Compared to Pure Low-Grade and High-Grade Urothelial Carcinomas.","authors":"Fateme Khalatbari, Miremad Moafi-Madani, Ali Amin","doi":"10.5858/arpa.2023-0367-OA","DOIUrl":null,"url":null,"abstract":"<p><strong>Context.—: </strong>Low-grade urothelial carcinoma (LGUC) and high-grade urothelial carcinoma (HGUC) are distinguished based on architectural and cytological features, with the anticipation that HGUC exhibits more aggressive behavior and a worse prognosis compared to LGUC. The current World Health Organization classification recognizes mixed-grade urothelial carcinoma (MGUC, for the purposes of this study) as a separate category that behaves like LGUC if the high-grade component is <5% and states that any tumor with ≥5% high-grade component should be graded as HGUC.</p><p><strong>Objective.—: </strong>To evaluate the risk of tumor recurrence, grade, and stage progression of MGUC compared to LGUC and HGUC.</p><p><strong>Design.—: </strong>A total of 150 de novo noninvasive polypoid urothelial carcinomas (41 cases of MGUC, 59 of LGUC, and 50 of HGUC) were included. Tumor recurrence, grade, and stage progression were compared among the MGUC, LGUC, and HGUC cases.</p><p><strong>Results.—: </strong>Tumor recurrence was observed in 14 of 41 (34.2%) of MGUC, 33 of 59 (55.9%) of LGUC, and 28 of 50 (56%) of HGUC. Grade progression occurred in 5 of 41 (12.2%) of MGUC cases and 5 of 59 (8.5%) of LGUC cases. No stage progression was observed in LGUC or MGUC cases, while 7 of 50 (14%) of HGUC cases showed stage progression. MGUC was associated with lower odds and hazard of recurrence compared to LGUC. The rate of grade progression was higher in MGUC and occurred after a shorter interval compared to LGUC.</p><p><strong>Conclusions.—: </strong>MGUC showed a prognosis closer to LGUC. Our study supports the current recommendation to classify tumors with <5% high-grade component as MGUC, as these tumors display clinical characteristics and outcomes close to that of pure LGUC.</p>","PeriodicalId":93883,"journal":{"name":"Archives of pathology & laboratory medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of pathology & laboratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5858/arpa.2023-0367-OA","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Context.—: Low-grade urothelial carcinoma (LGUC) and high-grade urothelial carcinoma (HGUC) are distinguished based on architectural and cytological features, with the anticipation that HGUC exhibits more aggressive behavior and a worse prognosis compared to LGUC. The current World Health Organization classification recognizes mixed-grade urothelial carcinoma (MGUC, for the purposes of this study) as a separate category that behaves like LGUC if the high-grade component is <5% and states that any tumor with ≥5% high-grade component should be graded as HGUC.

Objective.—: To evaluate the risk of tumor recurrence, grade, and stage progression of MGUC compared to LGUC and HGUC.

Design.—: A total of 150 de novo noninvasive polypoid urothelial carcinomas (41 cases of MGUC, 59 of LGUC, and 50 of HGUC) were included. Tumor recurrence, grade, and stage progression were compared among the MGUC, LGUC, and HGUC cases.

Results.—: Tumor recurrence was observed in 14 of 41 (34.2%) of MGUC, 33 of 59 (55.9%) of LGUC, and 28 of 50 (56%) of HGUC. Grade progression occurred in 5 of 41 (12.2%) of MGUC cases and 5 of 59 (8.5%) of LGUC cases. No stage progression was observed in LGUC or MGUC cases, while 7 of 50 (14%) of HGUC cases showed stage progression. MGUC was associated with lower odds and hazard of recurrence compared to LGUC. The rate of grade progression was higher in MGUC and occurred after a shorter interval compared to LGUC.

Conclusions.—: MGUC showed a prognosis closer to LGUC. Our study supports the current recommendation to classify tumors with <5% high-grade component as MGUC, as these tumors display clinical characteristics and outcomes close to that of pure LGUC.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
混合分级尿路上皮癌:与纯粹的低分级和高级别尿路上皮癌相比,对临床行为和预后影响的见解。
内涵:低级别尿路上皮癌(LGUC)和高级别尿路上皮癌(HGUC)是根据结构和细胞学特征区分的,预计与低级别尿路上皮癌相比,高级别尿路上皮癌更具侵袭性,预后更差。目前世界卫生组织的分类将混合型尿路上皮癌(MGUC,在本研究中称为混合型尿路上皮癌)作为一个单独的类别,如果高级别成分是客观存在的,则其表现与 LGUC 相似:与 LGUC 和 HGUC 相比,评估 MGUC 的肿瘤复发风险、级别和分期进展:共纳入 150 例新发的非浸润性多发性尿路上皮癌(41 例 MGUC、59 例 LGUC 和 50 例 HGUC)。比较了MGUC、LGUC和HGUC病例的肿瘤复发、分级和分期进展情况:41例MGUC中有14例(34.2%)观察到肿瘤复发,59例LGUC中有33例(55.9%)观察到肿瘤复发,50例HGUC中有28例(56%)观察到肿瘤复发。41例MGUC中有5例(12.2%)出现分期进展,59例LGUC中有5例(8.5%)出现分期进展。在 LGUC 或 MGUC 病例中未观察到分期进展,而在 50 例 HGUC 病例中有 7 例(14%)出现分期进展。与LGUC相比,MGUC的复发几率和风险较低。与LGUC相比,MGUC的分期进展率更高,间隔时间更短:结论:MGUC的预后更接近LGUC。我们的研究支持目前的建议,将肿瘤分为
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Analytical and Clinical Validation of the Oncomine Dx Target Test to Assess HER2 Mutation Status in Tumor Tissue Samples From Patients With Non-Small Cell Lung Cancer Treated With Trastuzumab Deruxtecan in the DESTINY-Lung01 and DESTINY-Lung02 Studies. Ethical and Regulatory Perspectives on Generative Artificial Intelligence in Pathology. Reduced Plasma Selenoprotein P Is Associated With Type I Antithrombin Deficiency and a Prothrombotic State. The Anatomic Pathology Hospitalist Model. Histologic Features of Liver Injury Associated With SARS-CoV-2 Messenger RNA Vaccines.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1